Related Experiment Videos
Ototoxicity of cisplatin.
International Journal of Andrology
|February 1, 1987
Summary
Cisplatin treatment for gynecological cancer can cause hearing loss, primarily in higher frequencies. Audiometric monitoring is recommended for patients receiving high-dose cisplatin regimens.
Area of Science:
- Oto-oncology
- Clinical Pharmacology
Background:
- Ototoxicity is a significant adverse effect of cisplatin chemotherapy.
- Hearing impairment, particularly in higher frequencies, is an early indicator of cisplatin-induced ototoxicity.
Purpose of the Study:
- To investigate the ototoxic effects of a moderate dose of cisplatin in women undergoing treatment for gynecological cancer.
- To determine the necessity of audiometric monitoring in patients receiving specific cisplatin regimens.
Main Methods:
- A cohort of 186 women with gynecological cancer treated with cisplatin (50 mg/m2 every 4 weeks) was studied.
- Hearing function was assessed, focusing on the speech frequency range.
Main Results:
- No significant hearing loss was observed within the speech frequency range in the studied cohort.
- Ototoxicity symptoms typically manifest 3-4 days post-cisplatin administration, affecting higher frequencies.
Conclusions:
- Moderate-dose cisplatin therapy for gynecological cancer did not result in significant hearing loss in the speech frequency range.
- Systemic audiometric monitoring is advised for cisplatin regimens involving single high-dose injections due to higher inner ear drug concentrations.